DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Still a Buy?

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $18.80, but opened at $20.19. DBV Technologies shares last traded at $20.9450, with a volume of 225,306 shares changing hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on DBVT shares. Citizens Jmp boosted their target price on DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a research report on Wednesday, December 17th. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Cantor Fitzgerald set a $48.00 target price on shares of DBV Technologies in a research note on Wednesday, December 17th. HC Wainwright set a $40.00 price target on shares of DBV Technologies in a research report on Thursday, December 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Stock Performance

The stock has a market cap of $831.31 million, a price-to-earnings ratio of -4.00 and a beta of -1.17. The business has a 50-day simple moving average of $16.53 and a two-hundred day simple moving average of $13.07.

Insider Buying and Selling

In other news, major shareholder Bpifrance Epic sold 1,292,103 shares of the stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the completion of the transaction, the insider directly owned 7,303,369 shares in the company, valued at $30,601,116.11. This represents a 15.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.44% of the stock is owned by company insiders.

Institutional Trading of DBV Technologies

Institutional investors and hedge funds have recently bought and sold shares of the stock. New York State Common Retirement Fund bought a new position in DBV Technologies in the third quarter valued at approximately $34,000. GAMMA Investing LLC boosted its holdings in shares of DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after buying an additional 744 shares during the last quarter. Two Sigma Investments LP bought a new position in shares of DBV Technologies in the third quarter valued at $167,000. Citadel Advisors LLC acquired a new position in DBV Technologies during the third quarter worth $220,000. Finally, DLD Asset Management LP acquired a new position in DBV Technologies during the third quarter worth $250,000. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.